SYRS — Syros Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $0.01m
- -$17.18m
- $9.94m
Annual income statement for Syros Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.98 | 15.1 | 23.5 | 14.9 | 9.94 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 79.7 | 97.4 | 123 | 151 | 139 |
| Operating Profit | -77.7 | -82.3 | -99.4 | -136 | -129 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -75.4 | -84 | -86.6 | -94.7 | -165 |
| Net Income After Taxes | -75.4 | -84 | -86.6 | -94.7 | -165 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -75.4 | -84 | -86.6 | -94.7 | -165 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -75.4 | -84 | -86.6 | -94.7 | -165 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -18.8 | -18.2 | -13.8 | -6.74 | -5.72 |